An ancillary or molecular test is a medical test for a patient that is not a part of the original study design. There are a wide variety of ancillary tests…
Read More
Dr. Matthew O. Leavitt is a Stanford-trained pathologist focused on innovation in digital pathology. He has 19 years of pathology experience. He founded Lumea and then became the founder and…
COVID-19 led to an unexpected rise in the practice of digital pathology. Temporary regulations were put in place to protect pathologists and other healthcare professionals, making diagnosing from a safe…
Related posts: Top 10 AI Companies for Digital Pathology Top 6 Reasons to use Genetic Tests for Pathology Best Resources for Pathologists – Podcast Artificial Intelligence In Digital Pathology –…
Wyatt Anthony is a pathologists’ assistant, has worked in anatomic pathology for 13 years, and, like many people who have worked in a lab, he hates prostate biopsies. Ever since…
Artificial intelligence and the digital world are invading many job sites worldwide, sometimes displacing jobs and, in other cases, creating new ones. As it infiltrates the world of pathology, some…
LEHI, UTAH, USA — June 1, 2022 — Lumea Inc, a global leader in integrated digital pathology solutions, is pleased to announce the first-of-its-kind Digital Diagnostic Summit in Park City,…
Lumea Inc., a global leader in integrated digital pathology solutions, is pleased to announce the first-of-its-kind Digital Diagnostic Summit in Park City, Utah. Today, Lumea announces the presenters for the…
Related posts: Verily and Lumea Announce Development Partnership Alphabet’s Life Sciences Arm is Partnering with Lumea Lumea Announces Presenters for the 2022 Digital Diagnostic Summit BioVantra Partners with Lumea
Digital pathology has recently been transformed by emerging advanced technology, creating new opportunities for practices. While many still hesitate to take the plunge and adopt digital pathology, the benefits cannot…
